Related Experiment Video
Updated: May 24, 2026
11:06
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Pioglitazone in clinical practice: where are we now?
1Department of Diabetes, University Hospital Llandough, Cardiff, Wales, UK.
Summary
Pioglitazone effectively lowers blood glucose and may offer cardiovascular benefits for type 2 diabetes patients. However, emerging evidence links this drug to an increased bladder cancer risk, necessitating a careful risk-benefit assessment.
Area of Science:
- Endocrinology and Metabolism
- Oncology
- Pharmacology
Background:
- Pioglitazone, a thiazolidinedione, enhances insulin sensitivity to reduce blood glucose levels.
- Clinical studies indicate potential cardiovascular benefits of pioglitazone.
- Growing safety concerns include a potential association between pioglitazone and bladder cancer risk.
Purpose of the Study:
- To critically appraise the current evidence regarding the risk-benefit profile of pioglitazone.
- To contextualize the role of pioglitazone in type 2 diabetes management.
- To evaluate the safety and efficacy of pioglitazone in light of recent findings.
Main Methods:
- Systematic review of existing clinical trial data.
- Critical appraisal of epidemiological studies on pioglitazone and cancer risk.
- Analysis of pharmacological data on insulin sensitivity and cardiovascular effects.
Main Results:
- Pioglitazone demonstrates efficacy in improving glycemic control and may confer cardiovascular advantages.
- Evidence suggests a possible increased risk of bladder cancer with pioglitazone use.
- The overall risk-benefit balance requires careful consideration for individual patient profiles.
Conclusions:
- Pioglitazone offers benefits for type 2 diabetes but carries potential risks, notably bladder cancer.
- Further research is needed to fully elucidate the long-term safety and efficacy of pioglitazone.
- Personalized treatment decisions for type 2 diabetes should weigh the benefits against the risks of pioglitazone.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...